Furthermore, a large Australian study of 431 patients with prostate cancer found the PSMA-PET scan to be a valuable diagnostic tool in the management of patients with prostate cancer, as the uptake of 68GA-labeled PSMA marker allowed the detection of unsuspected disease in the prostate bed, local lymph nodes, and distant metastases, which had not been detected by other imaging techniques. Here, FOLH1 is linked to prostate cancer.